vimarsana.com

Latest Breaking News On - Difficile - Page 1 : vimarsana.com

PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify. | May 9, 2023

United kingdomUnited statesJeffreyl silberRajita menonHuman servicesBiomedical advanced researchPuretech healthAmerican gastroenterological associationAmerican society for gastrointestinal endoscopyDepartment of healthSociety for surgery of the alimentary tractDevelopment authorityUniversity of massachusetts medical schoolSinai school of medicineDrug administrationAdministration for strategic preparedness

PureTech Founded Entity Vedanta Biosciences Announces $106 5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q. | April 25, 2023

United statesSouth koreaUnited kingdomMartin heideckerAtlantic neptuneCurt labelleBernat olleChristopher viehbacherBharatt chowriraNeil tiwariDepartment of healthKorea investment securities us incBiomedical advanced researchDevelopment authorityJournal of the american medical associationPuretech health

Soulstring Media Group: CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C difficile

Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York (Newsfile

New yorkUnited statesDavid luciSchwierige zeitenSoulstring media groupAcurx pharmaceuticals incAcurx pharmaceuticalsYork newsfile corpSoulstring media group llcDrug administrationMedia groupGram positive selective spectrumQualified infectious disease productGenerating new antibiotic incentives nowPrivate securities litigation reform act

DelveInsight Business Research, LLP: Clostridium difficile Infection Market to Show Immense Growth at a CAGR of 12 5% During the Study Period (2019-2032)

The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes

United statesShruti thakurSab biotherapeuticsKostenloser wertpapierhandelIndustria quimica farmaceutica nacionalRaqualia pharmaEisai coArmata pharmaceuticalsAcurx pharmaceuticalsRecursion pharmaceuticalsInfection companiesHealthcare due diligence servicesHealth scienceFerring pharmaceuticalsMicropharm ltdMarket research

Seres Therapeutics ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

– Summarized data from the study s secondary endpoints show investigational oral microbiome therapeutic rapidly and durably lowered risk of recurrent C. difficile infection – . | October 19, 2022

United statesCenters for diseaseExchange commissionSeres therapeutics incDrug administrationJournal of the american medical associationSeres therapeuticsAmerican medical associationDisease controlChief medical officerNew england journalMicrobiome therapeuticRecurrent clostridioidesRandomized clinicalBiologics license applicationOrphan drug

vimarsana © 2020. All Rights Reserved.